Closed Loop Insulin Therapy in Type 1 Diabetics Based on Blood Microdialysis, Online Sensors and an eMPC Algorithm - Full Text View

Purpose

The EU funded project CLINICIP (Closed Loop Insulin Infusion for Critically Ill Patients) aims to develop a low-risk monitoring and control device which allows maintaining metabolic control in intensive care units. A system will be developed comprising three subsystems: a body interface for the delivery of biofluids, biosensors for the determination of glucose concentration in these biofluids and an adaptive control algorithm that generates advice and thus represents a decision support system with respect to insulin infusion rate to establish glycaemic control in critically ill patients. Within a closed loop system, intensified insulin treatment will make use of the calculations leading to external regulation of glucose.

It is the aim of this study to evaluate the feasibility to establish glycaemic control in type 1 diabetic subjects over a period of 30 hours by manually combining these three - previously tested - subsystems (ABS System, extracorporeal online glucose sensor and a laptop-based computer algorithm).

Condition

Type 1 Diabetes

MedlinePlus related topics:

Diabetes Diabetes Type 1

ChemIDplus related topics:

Insulin Dextrose

U.S. FDA Resources

Study Type:	Observational
Study Design:	Cross-Sectional, Defined Population, Prospective Study

Official Title:	An Open, Mono-Centre Pilot Study to Investigate a Novel Technique to Establish Glycaemic Control for Critically Ill Patients, Tested in Type 1 Diabetic Subjects for a Period of 30 Hours.

Further study details as provided by Medical University of Graz:

Enrollment:	4
Study Start Date:	August 2007
Study Completion Date:	September 2007

Eligibility

Ages Eligible for Study:	18 Years to 65 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Signed informed consent obtained before any trial-related activities
Age of analysable subjects in the range from 18 to 65 years
Type 1 diabetes (Treatment with multiple daily injection for more than 12 months)

Exclusion Criteria:

Severe acute and/or chronic diseases
Mental incapacity, unwillingness or language barriers precluding adequate understanding or co-operation
Taking of any vasoactive substances or anticoagulation medication.
Diseases of the skin which could interfere with application of the catheters.
Pregnancy or breastfeeding
Bleeding disorder
Known heparin allergy or heparin intolerance

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00535483

Locations


Austria, Styria
	Medical University Graz - Clinical Research Center
	Graz, Styria, Austria, 8036

Sponsors and Collaborators

Medical University of Graz

Investigators


Principal Investigator:	Thomas R Pieber, MD	Medical University Graz, Graz, Austria

More Information

(CLINICIP (background information about the overall project)) This link exits the ClinicalTrials.gov site

(Healthsite (background information to the study site and investigators)) This link exits the ClinicalTrials.gov site

Related Info This link exits the ClinicalTrials.gov site

Study ID Numbers:	ABS3
First Received:	September 24, 2007
Last Updated:	September 24, 2007
ClinicalTrials.gov Identifier:	NCT00535483
Health Authority:	Austria: Ethikkommission

Keywords provided by Medical University of Graz:

blood microdialysis

glucose monitoring

glucose control

automated blood sampling

online-sensor

algorithm

type 1 diabetes

Study placed in the following topic categories:

Autoimmune Diseases

Metabolic Diseases

Diabetes Mellitus, Type 1

Critical Illness

Diabetes Mellitus

Endocrine System Diseases

Endocrinopathy

Metabolic disorder

Glucose Metabolism Disorders

Insulin

Additional relevant MeSH terms:

Immune System Diseases

ClinicalTrials.gov processed this record on October 03, 2008

Sponsored by:	Medical University of Graz
Information provided by:	Medical University of Graz
ClinicalTrials.gov Identifier:	NCT00535483